- Home
- SYNX vs LPTX Comparison
SYNX vs LPTX Comparison
Compare SYNX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- LPTX
- Stock Information
- Founded
- SYNX 2005
- LPTX 2011
- Country
- SYNX Israel
- LPTX United States
- Employees
- SYNX N/A
- LPTX N/A
- Industry
- SYNX
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYNX
- LPTX Health Care
- Exchange
- SYNX Nasdaq
- LPTX Nasdaq
- Market Cap
- SYNX 11.4M
- LPTX 11.1M
- IPO Year
- SYNX 2024
- LPTX N/A
- Fundamental
- Price
- SYNX $1.68
- LPTX $0.30
- Analyst Decision
- SYNX
- LPTX Hold
- Analyst Count
- SYNX 0
- LPTX 1
- Target Price
- SYNX N/A
- LPTX N/A
- AVG Volume (30 Days)
- SYNX 31.0K
- LPTX 2.1M
- Earning Date
- SYNX 10-02-2025
- LPTX 08-14-2025
- Dividend Yield
- SYNX N/A
- LPTX N/A
- EPS Growth
- SYNX N/A
- LPTX N/A
- EPS
- SYNX N/A
- LPTX N/A
- Revenue
- SYNX $9,094,000.00
- LPTX N/A
- Revenue This Year
- SYNX $32.35
- LPTX N/A
- Revenue Next Year
- SYNX N/A
- LPTX N/A
- P/E Ratio
- SYNX N/A
- LPTX N/A
- Revenue Growth
- SYNX 19.14
- LPTX N/A
- 52 Week Low
- SYNX $1.50
- LPTX $0.22
- 52 Week High
- SYNX $6.49
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- SYNX 45.37
- LPTX 47.39
- Support Level
- SYNX $1.57
- LPTX $0.26
- Resistance Level
- SYNX $1.75
- LPTX $0.31
- Average True Range (ATR)
- SYNX 0.14
- LPTX 0.04
- MACD
- SYNX -0.01
- LPTX -0.00
- Stochastic Oscillator
- SYNX 41.90
- LPTX 44.76
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.